FDA Approves Sutent for Rare Type of Pancreatic Cancer

SILVER SPRING, Md., May 20, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Sutent (sunitinib) to treat patients with progressive neuroendocrine cancerous tumors located in the pancreas that cannot be removed by surgery or that have spread to other parts of the body (metastatic).



Neuroendocrine tumors found in the pancreas are slow-growing and rare. It is estimated that there are fewer than 1,000 new cases in the United States each year.
This is the second new approval by the FDA to treat patients with this disease; on May 5, the agency approved Afinitor (everolimus).
"FDA believes it is important to provide cancer patients with as many treatment options as possible," said Richard Pazdur, M.D., director of the Office of Oncology Drug Products in the FDA's Center for Drug Evaluation and Research. "The agency is committed to working with companies to bring innovative new therapies to the market and encourages companies to continue exploring additional uses for approved products."

The safety and effectiveness of Sutent was established in a single study of 171 patients with metastatic (late-stage) or locally advanced (disease that could not be removed with surgery) disease who received Sutent or a placebo (sugar pill). The study was designed to measure the length of time a patient lived before their disease spread or worsened (progression-free survival).

Results from the study demonstrate that Sutent provided benefit to patients by prolonging the median length of time they lived without the cancer spreading or worsening to 10.2 months compared to 5.4 months for patients who received placebo.
In patients treated with Sutent for neuroendocrine pancreatic tumors, the most commonly reported side effects included diarrhea, nausea, vomiting, fatigue, anorexia, high blood pressure, energy loss (asthenia), stomach (abdominal) pain, changes in hair color, inflammation of the mouth (stomatitis), and a decrease in infection-fighting white blood cells (neutropenia).
Sutent is also FDA-approved to treat patients with late-stage kidney cancer (metastatic renal cell carcinoma) and to treat patients with GIST (gastrointestinal stromal tumor), a rare cancer of the stomach, bowel, or esophagus.

Sutent is marketed by New York City-based Pfizer.
For more information:




Web Site: http://www.fda.gov/

Comments

Post a Comment

Popular posts from this blog

Pharmacy Examining Board of Canada Questions & Answers

Image
Overview Q1 What is the Pharmacy Examining Board of Canada? The Pharmacy Examining Board of Canada ( PEBC ) is the national certification body for the pharmacy profession in Canada. PEBC is a non-profit organization with more than 40 years of experience in assessing the qualifications and competence of candidates for licensing by pharmacy provincial regulatory authorities. Established by Special Act of Parliament on December 21,1963, PEBC functions as an arms-length national examining board for pharmacists seeking entry-to-practice licensure in Canada. Q2 What is the purpose of the PEBC?
Read more

Paints in pharmacy| glycerin borax preparation is the first

Image
(1) GLYCERIN BORAX PREPARATION 13% Borax 13gm Glycerin to 100ml Levigate the borax powder into a suitable amount of glycerin then complete to 100ml.  Glycerin of borax uses: Used as a soothing agent in mouth ulcers also used in nipple fissures. (2) GLYCERIN TANNIC ACID PAINT 15% Tannic acid 15gm Glycerin to 100 ml Astringent in spongy gum and sore throat and applied to eyelid in trachoma. 1g of Na-citrate can be added (3) Glycerin borax and Tr.benzoin SOLUTION Glycerin borax 20 ml Tr.benzoin 10 ml Used in nipple fissure (4) DENTAL GLYCERIN ( zinc chloride) ZnCL2 1gm Glycerin 1.6ml H2O 0.5ml Alcohol 1.5ml used for de-sensation for exposed dentin (5) GENTIAN VIOLET PAINT (Rosaniline dyes) Gentian violet 1 gm Alcohol 70% 100 ml Used as antiseptic and in moniliasis. 2g of G. V can be used with 100 ml of glycerin borax in breast fissures. (6) ALCOHOLIC MERCUROCHROME PAINT Mercurochrome 2gm Alcohol 70% to 100 ml (7) Mercurochrom...
Read more

Facts about SOVALDI Therapy

Image
SOVALDI  It is a nucleotide analog polymerase inhibitor, that use in patients with chronic hepatitis C, in combination with ribavirin or interferon plus ribavirin, and the cure rate in clinical trials reached 95%. Here is some facts about SOVALDI that pharmacist must know: Active constituent of SOVALDI is sofosbuvir 400 mg. SOVALDI is effective against the four genotypes of HIV infection, including patients with HCC that in waiting list for liver transplantation, and those carrying HIV-1/HCV co-infection. SOVALDI not recommended using alone for Chronic Hepatitis C patients. The dose of SOVALDI is 400 mg once daily, to be taken regardless of food. Genotype-1 HCV treated for 12 weeks with SOVALDI +Peginterferon alfa +ribavirin, and for 24 weeks if used without peginterferon alfa. Genotype-2 HCV treated for 12 weeks with SOVALDI +ribavirin. Genotype-3 HCV treated for 24 weeks with SOVALDI +ribavirin. Genotype-4 treated for 12 weeks with SOVALDI +Peginterferon a...
Read more